{
  "id": 17811184,
  "title": "Why is uniQure stock sliding today?",
  "url": "https://urgent.news/2026/11/02/why-is-uniqure-stock-sliding-today",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-02T14:57:04.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/stock-market-news/why-is-uniqure-stock-sliding-today-93CH-4992152"
  },
  "original_language": "en",
  "account": "uniQure stock is experiencing a significant drop of approximately 5.7% in early trading following the FDA's acceptance of its Biologics License Application for ifezuntirgene inilparvovec, the investigational one-time gene therapy for Huntington's disease. The drug received Priority Review under the Accelerated Approval pathway, with a PDUFA target action date set for May 1, 2027. The initial surge in shares, up by roughly 2.5% in pre-market trading, erased earlier gains and pushed the stock to $26.14 before reversing course. Analysts attribute the sell-off to concerns about the 4-year follow-up data, which revealed a slower slowing of disease progression compared to earlier data. The FDA's acceptance letter also mentioned plans to convene an Advisory Committee, adding procedural uncertainty to the approval process. The uncertainty surrounding the Advisory Committee process and the potential impact of the therapy's clinical benefit have caused investors to question the stock's current valuation, with the price trading at $23.41, well below its 52-week high of $51.72.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}